Dr. Finkelstein obtained his Doctor of Medicine from Washington University in St. Louis in 1980. He then completed his residency in Internal Medicine at Northwestern University before coming to Massachusetts General Hospital in 1983 for specialty training in Endocrinology. He is currently an Associate Professor of Medicine at Harvard Medical School and a Physician at Massachusetts General Hospital, as well as the Associate Director of the MGH Bone Density Center. He has served on several national committees, including the American Board of Internal Medicine Sub-specialty Board on Endocrinology, Diabetes, and Metabolism, and has received several awards including election to the American Society for Clinical Investigation. He is recognized as in international expert on osteoporosis in men and is currently a member of the Endocrine Society Clinical Practice Guidelines Taskforce for Osteoporosis in Men.
In addition to being a busy clinical investigator, Dr. Finkelstein is an active and experienced clinician with particular interest and expertise in patients with bone and mineral disorders and men with testosterone deficiency.
Dr. Finkelstein has several research interests. He is the Principal Investigator on an NIH-funded project to determine the relationships between sex steroids and bone metabolism, body composition, sexual function and other processes in men. He is also the Principal Investigator at MGH for the Study of Women's Health Across the Nation (SWAN), a long-term, multi-ethnic, longitudinal study of the menopause transition whose goal is to describe the effects of the menopause transition on a wide variety of issues important to women's health at mid-life, including bone loss. He has several other major research interests including the use of parathyroid hormone to treat osteoporosis and new technologies to assess changes in bone mass. His work has been published in many prestigious journals including numerous papers in the New England Journal of Medicine and JAMA. He is the author of the chapter on Osteoporosis in the last 3 editions of Cecil Textbook of Medicine.
PublicationsSelected references from over 100 publications:
Finkelstein JS, Neer RM, Biller BMK, Crawford JD, Klibanski A.Osteopenia in adult men with histories of delayed puberty. N Engl J Med 326:600-4;1992
Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS. Hypovitaminosis D in medical inpatients. N Engl J Med 338:777-83, 1998
Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld D, Kantoff PW, Finkelstein JS.Pamidronate to prevent bone loss in men receiving gonadotropin-releasing hormone agonist therapy for prostate cancer.N Engl J Med 354:948-55, 2001
Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee Hang, Neer RM.Effects of parathyroid hormone, alendronate, or both in men with osteoporosis.N Engl J Med 349:1216-26, 2003
A study by MGH researchers finds that some of the symptoms often seen in middle-aged men – changes in body composition, energy, strength and sexual function – are caused not only by decreases in testosterone production but also by reduced levels of estrogen.